Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8806 to 8820 of 8885 results

  1. Supporting innovation: clear approval pathways and evidence standards for AI-driven digital health technologies

    Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.

  2. NICE partners with international health technology assessment bodies

    Six health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.

  3. Hundreds of children with type 2 diabetes to be offered choice of two life changing technologies

    Children with type 2 diabetes who currently manage their condition with the stressful task of finger prick testing several times a day could be offered a choice between two ‘life changing’ technologies to virtually automate the process.

  4. Draft guidance recommends healthcare professionals ask people about gambling

    Health professionals should ask people about gambling if they attend a health check or GP appointment with a mental health problem, in a similar way to how people are asked about their smoking and alcohol consumption, according to new draft guidance.

  5. The key to effective shared decision making is to involve people in meaningful conversations about their choices

    "Tell me and I forget. Teach me and I remember. Involve me and I learn." Benjamin Franklin.

  6. More people with rare genetic disorder eligible for nusinersen

    Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.

  7. Public consultation on updates to health technology evaluations manual

    A public consultation marking the first update to NICE's health technology evaluations manual is now open.

  8. Evidence Evusheld is effective in protecting vulnerable adults against variants lacking, as NICE announces new rapid update process for COVID-19 medicines

    NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.

  9. More people could be offered genetic testing for genes linked to ovarian cancer

    A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.

  10. Adapted shoes recommended for people with severe osteoarthritis

    People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.

  11. Targeted treatment for rare form of aggressive lung cancer gets NICE approval

    Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer

  12. New life-extending treatment for rare forms of advanced gastroesophageal cancer

    Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastroesophageal cancer after NICE published final draft guidance today (24 November 2022).

  13. Starting with the end in mind - the Innovative Licensing and Access Pathway

    The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.

  14. A 'safe space' for addressing complex health technology assessment challenges

    Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.

  15. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.